— Receives New Designation for Treatment of Platelet-Activating Anti-Platelet Factor 4 (PF4) Disorders — Complements FDA Orphan Drug Designation and Fast Track Designation for VLX-1005 Source: Veralox Frederick, MD, Aug. … Read more
thrombocytopenia
— Receives New Designation for Treatment of Platelet-Activating Anti-Platelet Factor 4 (PF4) Disorders — Complements FDA Orphan Drug Designation and Fast Track Designation for VLX-1005 Source: Veralox Frederick, MD, Aug. … Read more
© Copyright 2018 - 2024 FITCI. All Rights Reserved.
The Frederick Innovative Technology Center, Inc. (FITCI) is a 501(c)(3) nonprofit business incubator and accelerator designed to cultivate entrepreneurship in Frederick, Maryland.
Website Built by Wellspring Digital
